217 related articles for article (PubMed ID: 21352555)
1. Antitumor activity of mixed heat shock protein/peptide vaccine and cyclophosphamide plus interleukin-12 in mice sarcoma.
Guo QY; Yuan M; Peng J; Cui XM; Song G; Sui X; Lu SB
J Exp Clin Cancer Res; 2011 Feb; 30(1):24. PubMed ID: 21352555
[TBL] [Abstract][Full Text] [Related]
2. Prophylactic Antitumor Effect of Mixed Heat Shock Proteins/Peptides in Mouse Sarcoma.
Wang Y; Liu SY; Yuan M; Tang Y; Guo QY; Cui XM; Sui X; Peng J
Chin Med J (Engl); 2015 Aug; 128(16):2234-41. PubMed ID: 26265619
[TBL] [Abstract][Full Text] [Related]
3. A new antisarcoma strategy: multisubtype heat shock protein/peptide immunotherapy combined with PD-L1 immunological checkpoint inhibitors.
Li H; Sui X; Wang Z; Fu H; Wang Z; Yuan M; Liu S; Wang G; Guo Q
Clin Transl Oncol; 2021 Aug; 23(8):1688-1704. PubMed ID: 33792840
[TBL] [Abstract][Full Text] [Related]
4. Myeloma cell line-derived, pooled heat shock proteins as a universal vaccine for immunotherapy of multiple myeloma.
Qian J; Hong S; Wang S; Zhang L; Sun L; Wang M; Yang J; Kwak LW; Hou J; Yi Q
Blood; 2009 Oct; 114(18):3880-9. PubMed ID: 19654406
[TBL] [Abstract][Full Text] [Related]
5. IMA901: a multi-peptide cancer vaccine for treatment of renal cell cancer.
Kirner A; Mayer-Mokler A; Reinhardt C
Hum Vaccin Immunother; 2014; 10(11):3179-89. PubMed ID: 25625928
[TBL] [Abstract][Full Text] [Related]
6. Diminution of cyclophosphamide-induced suppression of antitumor immunity by an immunomodulator PS-K and combined therapeutic effects of PS-K and cyclophosphamide on transplanted tumor in rats.
Mizushima Y; Yuhki N; Hosokawa M; Kobayashi H
Cancer Res; 1982 Dec; 42(12):5176-80. PubMed ID: 7139621
[TBL] [Abstract][Full Text] [Related]
7. Long acting propranolol and HSP-70 rich tumor lysate reduce tumor growth and enhance immune response against fibrosarcoma in Balb/c mice.
Khalili A; Hassan ZM; Shahabi S; Pourfathollah AA; Ostad SN; Noori S; Mahdavi M; Haybar H; Langroudi L
Iran J Immunol; 2013 Jun; 10(2):70-82. PubMed ID: 23811546
[TBL] [Abstract][Full Text] [Related]
8. [Novel vaccines against M. tuberculosis].
Okada M
Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
[TBL] [Abstract][Full Text] [Related]
9. Significant antitumor effects obtained by autologous tumor cell vaccine engineered to secrete interleukin (IL)-12 and IL-18 by means of the EBV/lipoplex.
Asada H; Kishida T; Hirai H; Satoh E; Ohashi S; Takeuchi M; Kubo T; Kita M; Iwakura Y; Imanishi J; Mazda O
Mol Ther; 2002 May; 5(5 Pt 1):609-16. PubMed ID: 11991752
[TBL] [Abstract][Full Text] [Related]
10. A novel therapeutic fusion protein vaccine by two different families of heat shock proteins linked with HPV16 E7 generates potent antitumor immunity and antiangiogenesis.
Liu B; Ye D; Song X; Zhao X; Yi L; Song J; Zhang Z; Zhao Q
Vaccine; 2008 Mar; 26(10):1387-96. PubMed ID: 18272260
[TBL] [Abstract][Full Text] [Related]
11. Heat shock protein vaccines against cancer.
Blachere NE; Udono H; Janetzki S; Li Z; Heike M; Srivastava PK
J Immunother Emphasis Tumor Immunol; 1993 Nov; 14(4):352-6. PubMed ID: 8280719
[TBL] [Abstract][Full Text] [Related]
12. Chemo-immunotherapy of murine solid tumors: enhanced therapeutic effects by interleukin-2 combined with interferon alpha and the role of specific T cells.
Kedar E; Rutkowski Y; Leshem B
Cancer Immunol Immunother; 1992; 35(1):63-8. PubMed ID: 1611625
[TBL] [Abstract][Full Text] [Related]
13. IL-21 activates both innate and adaptive immunity to generate potent antitumor responses that require perforin but are independent of IFN-gamma.
Ma HL; Whitters MJ; Konz RF; Senices M; Young DA; Grusby MJ; Collins M; Dunussi-Joannopoulos K
J Immunol; 2003 Jul; 171(2):608-15. PubMed ID: 12847225
[TBL] [Abstract][Full Text] [Related]
14. Photodynamic therapy-generated tumor cell lysates with CpG-oligodeoxynucleotide enhance immunotherapy efficacy in human papillomavirus 16 (E6/E7) immortalized tumor cells.
Bae SM; Kim YW; Kwak SY; Kim YW; Ro DY; Shin JC; Park CH; Han SJ; Oh CH; Kim CK; Ahn WS
Cancer Sci; 2007 May; 98(5):747-52. PubMed ID: 17425690
[TBL] [Abstract][Full Text] [Related]
15. Immune response against large tumors eradicated by treatment with cyclophosphamide and IL-12.
Tsung K; Meko JB; Tsung YL; Peplinski GR; Norton JA
J Immunol; 1998 Feb; 160(3):1369-77. PubMed ID: 9570556
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy using heat-shock protein preparations of leukemia cells after syngeneic bone marrow transplantation in mice.
Sato K; Torimoto Y; Tamura Y; Shindo M; Shinzaki H; Hirai K; Kohgo Y
Blood; 2001 Sep; 98(6):1852-7. PubMed ID: 11535521
[TBL] [Abstract][Full Text] [Related]
17. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.
Pass HA; Schwarz SL; Wunderlich JR; Rosenberg SA
Cancer J Sci Am; 1998; 4(5):316-23. PubMed ID: 9815296
[TBL] [Abstract][Full Text] [Related]
18. HSP110-HER2/neu chaperone complex vaccine induces protective immunity against spontaneous mammary tumors in HER-2/neu transgenic mice.
Manjili MH; Wang XY; Chen X; Martin T; Repasky EA; Henderson R; Subjeck JR
J Immunol; 2003 Oct; 171(8):4054-61. PubMed ID: 14530326
[TBL] [Abstract][Full Text] [Related]
19. Characterization of heat shock protein 110 and glucose-regulated protein 170 as cancer vaccines and the effect of fever-range hyperthermia on vaccine activity.
Wang XY; Kazim L; Repasky EA; Subjeck JR
J Immunol; 2001 Jan; 166(1):490-7. PubMed ID: 11123328
[TBL] [Abstract][Full Text] [Related]
20. Gastric cancer-derived heat shock protein-gp96 peptide complex enhances dendritic cell activation.
Lu WW; Zhang H; Li YM; Ji F
World J Gastroenterol; 2017 Jun; 23(24):4390-4398. PubMed ID: 28706421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
